Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Price Crosses Below Two Hundred Day Moving Average – Should You Sell?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) shares crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.10 and traded as low as $0.5650. Galmed Pharmaceuticals shares last traded at $0.6616, with a volume of 72,145 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce”.

Galmed Pharmaceuticals Stock Performance

The firm has a market cap of $3.63 million, a price-to-earnings ratio of -2.07 and a beta of 0.40. The stock’s 50 day simple moving average is $0.75 and its 200-day simple moving average is $1.10.

Hedge Funds Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Two Sigma Investments LP purchased a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned 1.28% of Galmed Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 76.14% of the stock is owned by institutional investors.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.